Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Bacteriophage and antibiotic combination therapy for recurrent Enterococcus faecium bacteremia

Madison E. Stellfox, Carolyn Fernandes, View ORCID ProfileRyan K. Shields, View ORCID ProfileGhady Haidar, Kailey Hughes Kramer, Emily Dembinski, Mihnea R. Mangalea, Gregory S. Canfield, View ORCID ProfileBreck A. Duerkop, View ORCID ProfileDaria Van Tyne
doi: https://doi.org/10.1101/2022.11.23.22282657
Madison E. Stellfox
aDivision of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carolyn Fernandes
aDivision of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ryan K. Shields
aDivision of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ryan K. Shields
Ghady Haidar
aDivision of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ghady Haidar
Kailey Hughes Kramer
aDivision of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emily Dembinski
aDivision of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mihnea R. Mangalea
bDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory S. Canfield
bDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Breck A. Duerkop
bDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Breck A. Duerkop
Daria Van Tyne
aDivision of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Daria Van Tyne
  • For correspondence: vantyne@pitt.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Enterococcus faecium is a member of the human gastrointestinal (GI) tract microbiota but can also cause invasive infections, especially in immunocompromised hosts. Enterococci display intrinsic resistance to many antibiotics, and most clinical E. faecium isolates have acquired vancomycin resistance, leaving clinicians with a limited repertoire of effective antibiotics. As such, vancomycin-resistant E. faecium (VREfm) has become an increasingly difficult to treat nosocomial pathogen that is often associated with treatment failure and recurrent infections. We followed a patient with recurrent E. faecium bloodstream infections (BSIs) of increasing severity that ultimately became unresponsive to antibiotic combination therapy over the course of 7 years. Whole genome sequencing (WGS) showed that the patient was colonized with closely related E. faecium strains for at least two years, and that invasive isolates likely emerged from a large E. faecium population in the patient’s GI tract. The addition of bacteriophage (phage) therapy to the patient’s antimicrobial regimen was associated with several months of clinical improvement and reduced intestinal burden of VRE and E. faecium. Eventual recurrence of E. faecium BSI was not associated with the development of antibiotic or phage resistance in post-treatment isolates. However, an anti-phage neutralizing antibody response occurred simultaneously with an increased relative abundance of VRE in the GI tract, both of which may have contributed to clinical failure. Taken together, these findings highlight the potential utility and limitations of phage therapy to treat antibiotic-resistant enterococcal infections.

Importance Phage therapy is an emerging therapeutic approach for treating bacterial infections that do not respond to traditional antibiotics. The addition of phage therapy to systemic antibiotics to treat a patient with recurrent E. faecium infections that were non-responsive to antibiotics alone resulted in fewer hospitalizations and improved the patient’s quality of life. Combination phage and antibiotic therapy reduced E. faecium and VRE abundance in the patient’s stool. Eventually an anti-phage antibody response emerged that was able to neutralize phage activity, which may have limited clinical efficacy. This study demonstrates the potential of phages as an additional option in the antimicrobial toolbox for treating invasive enterococcal infections and highlights the need for further investigation to ensure phage therapy can be deployed for maximum clinical benefit.

Competing Interest Statement

GH is a recipient of research grants from Allovir, Karius, and AstraZeneca. GH also serves on the scientific advisory boards of Karius and AstraZeneca and has received honoraria from MDOutlook.

Clinical Trial

eIND #27183

Funding Statement

Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R01AI165519 (to DVT) and R21AI151363 (to RKS). This work was also supported by grants R01AI141479 (BAD), T32AR007534 (MRM), and K23AI154546 (GH) from the NIH. The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

FDA emergency investigational new drug approval for administration of phages was obtained (eIND #27183), and the Institutional Review Board at the University of Pittsburgh also approved the study (Protocol #EA20120145). The patient provided informed consent to participate in the study.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Genome sequencing data for all isolates was submitted to NCBI under BioProject PRJNA901969, with accession numbers listed in Supplemental Table 1. Other data presented are available upon reasonable request to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 01, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Bacteriophage and antibiotic combination therapy for recurrent Enterococcus faecium bacteremia
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Bacteriophage and antibiotic combination therapy for recurrent Enterococcus faecium bacteremia
Madison E. Stellfox, Carolyn Fernandes, Ryan K. Shields, Ghady Haidar, Kailey Hughes Kramer, Emily Dembinski, Mihnea R. Mangalea, Gregory S. Canfield, Breck A. Duerkop, Daria Van Tyne
medRxiv 2022.11.23.22282657; doi: https://doi.org/10.1101/2022.11.23.22282657
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Bacteriophage and antibiotic combination therapy for recurrent Enterococcus faecium bacteremia
Madison E. Stellfox, Carolyn Fernandes, Ryan K. Shields, Ghady Haidar, Kailey Hughes Kramer, Emily Dembinski, Mihnea R. Mangalea, Gregory S. Canfield, Breck A. Duerkop, Daria Van Tyne
medRxiv 2022.11.23.22282657; doi: https://doi.org/10.1101/2022.11.23.22282657

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (496)
  • Anesthesia (106)
  • Cardiovascular Medicine (1110)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (275)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (505)
  • Epidemiology (9796)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2327)
  • Geriatric Medicine (223)
  • Health Economics (463)
  • Health Informatics (1567)
  • Health Policy (737)
  • Health Systems and Quality Improvement (608)
  • Hematology (238)
  • HIV/AIDS (508)
  • Infectious Diseases (except HIV/AIDS) (11669)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (240)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2154)
  • Nursing (134)
  • Nutrition (340)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (519)
  • Oncology (1185)
  • Ophthalmology (366)
  • Orthopedics (129)
  • Otolaryngology (221)
  • Pain Medicine (148)
  • Palliative Medicine (50)
  • Pathology (314)
  • Pediatrics (699)
  • Pharmacology and Therapeutics (303)
  • Primary Care Research (268)
  • Psychiatry and Clinical Psychology (2195)
  • Public and Global Health (4685)
  • Radiology and Imaging (786)
  • Rehabilitation Medicine and Physical Therapy (458)
  • Respiratory Medicine (625)
  • Rheumatology (276)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (212)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)